Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of dolutegravir versus raltegravir in treatment-experienced adults with HIV-1
2009-018001-51Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Human immunodeficiency virus infection type 1 comparing Dolutegravir + optimized background regimen with Raltegravir + optimized background regimen (2 arms). Primary endpoint: Primary virologic response at Week 48. Started Aug 2010; status: completed.
02
Drugs
dolutegravirraltegravir
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2009-018001-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018001-51.